{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:37Z","timestamp":1791874717196,"version":"4.3.4"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T00:00:00Z","timestamp":1227571200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s11894-008-0108-6","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T15:44:58Z","timestamp":1227714298000},"page":"597-605","source":"Crossref","is-referenced-by-count":67,"title":["Extraintestinal manifestations of inflammatory bowel disease"],"prefix":"10.1007","volume":"10","author":[{"given":"Horace","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,25]]},"reference":[{"key":"108_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00054725-200405000-00005","volume":"10","author":"E. Ricart","year":"2004","unstructured":"Ricart E, Panaccione R, Loftus EV, et al.: Autoimmune disorders and extraintestinal manifestations in first degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004, 10:207\u2013214.","journal-title":"Inflamm Bowel Dis"},{"key":"108_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","volume":"55","author":"A.J. Greenstein","year":"1976","unstructured":"Greenstein AJ, Janowitz HD, Sachar DB: The extraintestinal complications of Crohn\u2019s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976, 55:401\u2013412.","journal-title":"Medicine (Baltimore)"},{"key":"108_CR3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","volume":"129","author":"C.N. Bernstein","year":"2005","unstructured":"Bernstein CN, Wajda A, Blanchard JF: The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005, 129:827\u2013836.","journal-title":"Gastroenterology"},{"key":"108_CR4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10620-007-9836-y","volume":"53","author":"M.S. Cappell","year":"2008","unstructured":"Cappell MS, Turkieh A: Chronic pericarditis and pericardial tamponade associated with ulcerative colitis. Dig Dis Sci 2008, 53:149\u2013154.","journal-title":"Dig Dis Sci"},{"key":"108_CR5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00431-007-0593-x","volume":"167","author":"T. Watanabe","year":"2008","unstructured":"Watanabe T: Parotitis and acute pancreatitis in a patient with ulcerative colitis. Eur J Pediatr 2008, 167:945.","journal-title":"Eur J Pediatr"},{"key":"108_CR6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ibd.20389","volume":"14","author":"S.S. Mahid","year":"2008","unstructured":"Mahid SS, Mulhall AM, Gholson RD, et al.: Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis 2008, 14:960\u2013967.","journal-title":"Inflamm Bowel Dis"},{"key":"108_CR7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1572-0241.2006.00504.x","volume":"101","author":"G.C. Nguyen","year":"2006","unstructured":"Nguyen GC, Torres EA, Regueiro M, et al.: Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006, 101:1012\u20131023.","journal-title":"Am J Gastroenterol"},{"key":"108_CR8","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/j.1572-0241.2005.00233.x","volume":"100","author":"D. Basu","year":"2005","unstructured":"Basu D, Lopez I, Kulkarni A, Sellin JH: Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005, 100:2254\u20132261.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl2","key":"108_CR9","first-page":"225","volume":"18","author":"V.E. Rodriguez","year":"2008","unstructured":"Rodriguez VE, Costas PJ, Vazquez M, et al.: Prevalence of spondyloarthropathy in Puerto Rican patients with inflammatory bowel disease. Ethn Dis 2008, 18(Suppl 2):225\u2013229.","journal-title":"Ethn Dis"},{"key":"108_CR10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10067-007-0797-5","volume":"27","author":"C.C. Lanna","year":"2008","unstructured":"Lanna CC, Ferrari M, Rocha SL, et al.: A cross-sectional study of 130 Brazilian patients with Crohn\u2019s disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol 2008, 27:503\u2013509.","journal-title":"Clin Rheumatol"},{"key":"108_CR11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0016-5085(00)70209-5","volume":"118","author":"T.R. Orchard","year":"2000","unstructured":"Orchard TR, Thiyagaraja S, Welsh KI, et al.: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118:274\u2013278.","journal-title":"Gastroenterology"},{"key":"108_CR12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1053\/gast.2002.35396","volume":"123","author":"T.R. Orchard","year":"2002","unstructured":"Orchard TR, Chua CN, Ahmad T, et al.: Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002, 123:714\u2013718.","journal-title":"Gastroenterology"},{"key":"108_CR13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1053\/gast.1997.v112.pm9178675","volume":"112","author":"M. Roussomoustakaki","year":"1997","unstructured":"Roussomoustakaki M, Satsangi J, Welsh K, et al.: Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997, 112:1845\u20131853.","journal-title":"Gastroenterology"},{"issue":"SupplIII","key":"108_CR14","first-page":"A21","volume":"56","author":"H.R.T. Williams","year":"2007","unstructured":"Williams HRT, Sato H, Welsh KI, et al.: Clinical and genetic associations of pyoderma gangrenosum in patients with inflammatory bowel disease: evidence for a shared predisposition to extraintestinal manifestations [abstract]. Gut 2007, 56(Suppl III):A21. Presented at United European Gastroenterology Week. Paris; October 2007.","journal-title":"Gut"},{"key":"108_CR15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2004.021774","volume":"63","author":"H. Peeters","year":"2004","unstructured":"Peeters H, Vander Cruyssen B, Laukens D, et al.: Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn\u2019s disease. Ann Rheum Dis 2004, 63:1131\u20131134.","journal-title":"Ann Rheum Dis"},{"key":"108_CR16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1440-1746.2007.05108.x","volume":"23","author":"H. Peeters","year":"2008","unstructured":"Peeters H, Vander Cruyssen B, Mielants H, et al.: Clinical and genetic factors associated with sacroiliitis in Crohn\u2019s disease. J Gastroenterol Hepatol 2008, 23:132\u2013137.","journal-title":"J Gastroenterol Hepatol"},{"key":"108_CR17","first-page":"2266","volume":"22","author":"H. Mielants","year":"1995","unstructured":"Mielants H, Veys EM, De Vos M, et al.: The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995, 22:2266\u20132272.","journal-title":"J Rheumatol"},{"key":"108_CR18","first-page":"1932","volume":"25","author":"D. Elewaut","year":"1998","unstructured":"Elewaut D, De Keyser F, Van Den Bosch F, et al.: Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998, 25:1932\u20131937.","journal-title":"J Rheumatol"},{"key":"108_CR19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","volume":"42","author":"T.R. Orchard","year":"1998","unstructured":"Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387\u2013391.","journal-title":"Gut"},{"issue":"Suppl1","key":"108_CR20","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","volume":"55","author":"S.P. Travis","year":"2006","unstructured":"Travis SP, Stange EF, L\u00e9mann M, et al.; European Crohn\u2019s and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn\u2019s disease: current management. Gut 2006, 55(Suppl 1):i16\u2013i35.","journal-title":"Gut"},{"key":"108_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1155\/2001\/612531","volume":"15","author":"G. Fornaciari","year":"2001","unstructured":"Fornaciari G, Salvarini C, Beltrami M, et al.: Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001, 15:399\u2013403.","journal-title":"Can J Gastroenterol"},{"key":"108_CR22","first-page":"518","volume":"30","author":"S. Steer","year":"2003","unstructured":"Steer S, Jones H, Hibbert J, Kondeatis, et al.: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn\u2019s disease. J Rheumatol 2003, 30:518\u2013522.","journal-title":"J Rheumatol"},{"key":"108_CR23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/ard.37.1.33","volume":"37","author":"B.J. Dekker-Saeys","year":"1978","unstructured":"Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, et al.: Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978, 37:33\u201335.","journal-title":"Ann Rheum Dis"},{"key":"108_CR24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/ard.55.4.268","volume":"55","author":"M.A. Brown","year":"1996","unstructured":"Brown MA, Pile KD, Kennedy LG, et al.: HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996, 55:268\u2013270.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl4","key":"108_CR25","first-page":"W1298","volume":"122","author":"T. Orchard","year":"2002","unstructured":"Orchard T, Holt H, Bradley L, et al.: Prevalence of sacroiliitis in Crohn\u2019s disease, and its correlation with clinical, radiologic and genotypic parameters [abstract]. Gastroenterology 2002, 122(Suppl 4):W1298.","journal-title":"Gastroenterology"},{"key":"108_CR26","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.22812","volume":"56","author":"B. Thjodleifsson","year":"2007","unstructured":"Thjodleifsson B, Geirsson AJ, Bj\u00f6rnsson S, Bjarnason I: A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007, 56:2633\u20132639.","journal-title":"Arthritis Rheum"},{"key":"108_CR27","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.23389","volume":"58","author":"P. Rahman","year":"2008","unstructured":"Rahman P, Inman RD, Gladman DD, et al.: Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008, 58:1020\u20131025.","journal-title":"Arthritis Rheum"},{"key":"108_CR28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"R.H. Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, et al.: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461\u20131463.","journal-title":"Science"},{"key":"108_CR29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M. Cargill","year":"2007","unstructured":"Cargill M, Schrodi SJ, Chang M, et al.: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273\u2013290.","journal-title":"Am J Hum Genet"},{"key":"108_CR30","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1572-0241.2000.02262.x","volume":"95","author":"J.B. Felder","year":"2000","unstructured":"Felder JB, Korelitz BI, Rajapakse R, et al.: Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000, 95:1949\u20131954.","journal-title":"Am J Gastroenterol"},{"key":"108_CR31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/gut.40.5.619","volume":"40","author":"J.M. Evans","year":"1997","unstructured":"Evans JM, McMahon AD, Murray FE, et al.: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619\u2013622.","journal-title":"Gut"},{"key":"108_CR32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","volume":"4","author":"K. Takeuchi","year":"2006","unstructured":"Takeuchi K, Smale S, Premshand P, et al.: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:196\u2013202.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"108_CR33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00054725-200411000-00009","volume":"10","author":"G.F. Bonner","year":"2004","unstructured":"Bonner GF, Fakhri A, Vennamaneni SR: A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:751\u2013757.","journal-title":"Inflamm Bowel Dis"},{"key":"108_CR34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/ard.61.suppl_3.iii40","volume":"61","author":"M. Dougados","year":"2002","unstructured":"Dougados M, Dijkmans B, Khan M, et al.: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002, 61:40\u201350.","journal-title":"Ann Rheum Dis"},{"key":"108_CR35","doi-asserted-by":"crossref","unstructured":"Chen J, Liu C, Lin J: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006, CD004524.","DOI":"10.1002\/14651858.CD004524.pub3"},{"key":"108_CR36","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"D.O. Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325\u20132329.","journal-title":"Arthritis Rheum"},{"key":"108_CR37","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","volume":"38","author":"M. Dougados","year":"1995","unstructured":"Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondyloarthropathy. A randomised, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618\u2013627.","journal-title":"Arthritis Rheum"},{"key":"108_CR38","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.1780390819","volume":"39","author":"A. Taggart","year":"1996","unstructured":"Taggart A, Gardiner P, McEvoy F, et al.: Which is the active moiety of sulfasalazine in ankylosing spondylitis? Arthritis Rheum 1996, 39:1400\u20131405.","journal-title":"Arthritis Rheum"},{"key":"108_CR39","first-page":"1558","volume":"30","author":"J.C. Denderen van","year":"2003","unstructured":"van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA: Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol 2003, 30:1558\u20131560.","journal-title":"J Rheumatol"},{"key":"108_CR40","first-page":"714","volume":"27","author":"G.T. Thomson","year":"2000","unstructured":"Thomson GT, Thomson BR, Thomson KS, Ducharme JS: Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000, 27:714\u2013718.","journal-title":"J Rheumatol"},{"key":"108_CR41","first-page":"723","volume":"27","author":"B.J. Dekker-Saeys","year":"2000","unstructured":"Dekker-Saeys BJ, Dijkmans BA, Tytgat GN: Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol 2000, 27:723\u2013726.","journal-title":"J Rheumatol"},{"key":"108_CR42","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4321\/S1130-01082005000800005","volume":"97","author":"O. Karimi","year":"2005","unstructured":"Karimi O, Pe\u00f1a AS: Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. Rev Esp Enferm Dig 2005, 97:570\u2013574.","journal-title":"Rev Esp Enferm Dig"},{"key":"108_CR43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0889-8553(21)00215-6","volume":"24","author":"J.B. Levine","year":"1995","unstructured":"Levine JB, Lukawski-Trubish D: Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Amer 1995, 24:633\u2013646.","journal-title":"Gastroenterol Clin North Amer"},{"key":"108_CR44","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","volume":"63","author":"S. Generini","year":"2004","unstructured":"Generini S, Giacomelli R, Fedi R, et al.: Infliximab in spondyloarthropathy associated with Crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664\u20131669.","journal-title":"Ann Rheum Dis"},{"key":"108_CR45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J. Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007, 57:639\u2013647.","journal-title":"Arthritis Rheum"},{"key":"108_CR46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.clindermatol.2007.10.018","volume":"26","author":"S. Timani","year":"2008","unstructured":"Timani S, Mutasim DF: Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008, 26:265\u2013273.","journal-title":"Clin Dermatol"},{"key":"108_CR47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","volume":"23","author":"F.T. Veloso","year":"1996","unstructured":"Veloso FT, Carvalho J, Magro F: Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol 1996, 23:29\u201334.","journal-title":"J Clin Gastroenterol"},{"key":"108_CR48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/pgmj.2004.031633","volume":"81","author":"L.B. Trost","year":"2005","unstructured":"Trost LB, McDonnell JK: Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005, 81:580\u2013585.","journal-title":"Postgrad Med J"},{"issue":"Suppl4","key":"108_CR49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2036.2004.02055.x","volume":"20","author":"F. Tavarela Veloso","year":"2004","unstructured":"Tavarela Veloso F: Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl 4):50\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"108_CR50","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(97)10187-8","volume":"351","author":"J.P. Callen","year":"1998","unstructured":"Callen JP: Pyoderma gangrenosum. Lancet 1998, 351:581\u2013585.","journal-title":"Lancet"},{"key":"108_CR51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.333.7560.181","volume":"333","author":"T. Brooklyn","year":"2006","unstructured":"Brooklyn T, Dunnill G, Probert C: Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006, 333:181\u2013184.","journal-title":"BMJ"},{"key":"108_CR52","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0190-9622(96)90285-6","volume":"34","author":"R.K. Chow","year":"1996","unstructured":"Chow RK, Ho VC: Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996, 34:1047\u20131060.","journal-title":"J Am Acad Dermatol"},{"key":"108_CR53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"T.N. Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, et al.: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505\u2013509.","journal-title":"Gut"},{"key":"108_CR54","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ncpgasthep0982","volume":"4","author":"M. Girardin","year":"2007","unstructured":"Girardin M, Waschke KA, Seidman EG: A case of acute loss of vision as the presenting symptom of Crohn\u2019s disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:695\u2013698.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"108_CR55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00054725-200403000-00012","volume":"10","author":"R. Mintz","year":"2004","unstructured":"Mintz R, Feller ER, Bahr RL, Shah SA: Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:135\u2013139.","journal-title":"Inflamm Bowel Dis"},{"key":"108_CR56","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11894-004-0073-7","volume":"6","author":"E.V. Loftus","year":"2004","unstructured":"Loftus EV: Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 2004, 6:506\u2013513.","journal-title":"Curr Gastroenterol Rep"},{"key":"108_CR57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2005.12.012","volume":"33","author":"S. Hale","year":"2006","unstructured":"Hale S, Lightman S: Anti-TNF therapies in the treatment of acute and chronic uveitis. Cytokine 2006, 33:231\u2013237.","journal-title":"Cytokine"},{"key":"108_CR58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.gie.2005.12.034","volume":"64","author":"S.L. Moff","year":"2006","unstructured":"Moff SL, Kamel IR, Eustace J, et al.: Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006, 64:219\u2013223.","journal-title":"Gastrointest Endosc"},{"key":"108_CR59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00001574-200405000-00013","volume":"20","author":"G.R. MacFaul","year":"2004","unstructured":"MacFaul GR, Chapman RW: Sclerosing cholangitis. Curr Opinion Gastroenterol 2004, 20:275\u2013280.","journal-title":"Curr Opinion Gastroenterol"},{"key":"108_CR60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.20287","volume":"40","author":"J.A. Talwalkar","year":"2004","unstructured":"Talwalkar JA, Angulo P, Johnson CD, et al.: Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39\u201345.","journal-title":"Hepatology"},{"key":"108_CR61","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","volume":"336","author":"K.D. Lindor","year":"1997","unstructured":"Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691\u2013695.","journal-title":"N Engl J Med"},{"key":"108_CR62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","volume":"121","author":"S.A. Mitchell","year":"2001","unstructured":"Mitchell SA, Bansi DA, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900\u2013907.","journal-title":"Gastroenterology"},{"key":"108_CR63","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","volume":"129","author":"R. Olsson","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell OS, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464\u20131472.","journal-title":"Gastroenterology"},{"key":"108_CR64","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1365-2036.2005.02407.x","volume":"21","author":"S.N. Cullen","year":"2005","unstructured":"Cullen SN, Chapman RW: Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 21:933\u2013948.","journal-title":"Aliment Pharmacol Ther"},{"key":"108_CR65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jhep.2004.01.002","volume":"40","author":"B. Brandsaeter","year":"2004","unstructured":"Brandsaeter B, Isoniemi H, Broome U, et al.: Liver transplantation for primary sclerosing cholangitis: predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815\u2013822.","journal-title":"J Hepatol"},{"key":"108_CR66","doi-asserted-by":"crossref","first-page":"v10","DOI":"10.1136\/gut.51.suppl_5.v10","volume":"51","author":"J.A. Eaden","year":"2002","unstructured":"Eaden JA, Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002, 51:v10\u2013v12.","journal-title":"Gut"},{"key":"108_CR67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2036.2005.02650.x","volume":"22","author":"J.M. Wolf","year":"2005","unstructured":"Wolf JM, Rybicki LA, Lashner BA: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783\u2013788.","journal-title":"Aliment Pharmacol Ther"},{"key":"108_CR68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","volume":"124","author":"D.S. Pardi","year":"2003","unstructured":"Pardi DS, Loftus EV, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889\u2013893.","journal-title":"Gastroenterology"},{"key":"108_CR69","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.3748\/wjg.v13.i46.6156","volume":"13","author":"L. Rodr\u00edguez-Bores","year":"2007","unstructured":"Rodr\u00edguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK: Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol 2007, 13:6156\u20136165.","journal-title":"World J Gastroenterol"},{"key":"108_CR70","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1046\/j.1365-2036.2002.01363.x","volume":"16","author":"E.J. Lamb","year":"2002","unstructured":"Lamb EJ, Wong T, Smith DJ, et al.: Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1895\u20131902.","journal-title":"Aliment Pharmacol Ther"},{"key":"108_CR71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.2003.026799","volume":"53","author":"T. Card","year":"2004","unstructured":"Card T, West J, Hubbard R, Logan RF: Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004, 53:251\u2013255.","journal-title":"Gut"},{"key":"108_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/aje\/kwf007","volume":"156","author":"P. Vestergaard","year":"2002","unstructured":"Vestergaard P, Mosekilde L: Fracture risk in patients with celiac disease, Crohn\u2019s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1\u201310.","journal-title":"Am J Epidemiol"},{"key":"108_CR73","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/gast.2003.50106","volume":"124","author":"C.N. Bernstein","year":"2003","unstructured":"Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795\u2013841","journal-title":"Gastroenterology"},{"key":"108_CR74","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/gast.2003.50107","volume":"124","author":"American Gastroenterological Association","year":"2003","unstructured":"American Gastroenterological Association: Medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791\u2013794.","journal-title":"Gastroenterology"},{"key":"108_CR75","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-004-1621-6","volume":"15","author":"S. Boonen","year":"2004","unstructured":"Boonen S, Rizzoli R, Meunier PJ, et al.: The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004, 15:511\u2013519.","journal-title":"Osteoporos Int"},{"key":"108_CR76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1572-0241.2006.00372.x","volume":"101","author":"S. Henderson","year":"2006","unstructured":"Henderson S, Hoffman N, Prince RA: Double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119\u2013123.","journal-title":"Am J Gastroenterol"},{"key":"108_CR77","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.rmed.2007.08.014","volume":"102","author":"A.A. Raj","year":"2008","unstructured":"Raj AA, Birring SS, Green R, et al.: Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med 2008, 102:780\u2013785.","journal-title":"Respir Med"},{"key":"108_CR78","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/gast.2002.36613","volume":"123","author":"H. Izzedine","year":"2002","unstructured":"Izzedine H, Simon J, Piette AM, et al.: Primary chronic interstitial nephritis in Crohn\u2019s disease. Gastroenterology 2002, 123:1436\u20131440.","journal-title":"Gastroenterology"},{"key":"108_CR79","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MPG.0b013e31806dc2c4","volume":"46","author":"S.B. Marcus","year":"2008","unstructured":"Marcus SB, Brown JB, Melin-Aldana H, Strople JA: Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr 2008, 46:338\u2013341.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"108_CR80","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/bmj.307.6903.540","volume":"307","author":"A.J. Archimandritis","year":"1993","unstructured":"Archimandritis AJ, Weetch MS: Kidney granuloma in Crohn\u2019s disease. BMJ 1993, 307:540\u2013541.","journal-title":"BMJ"},{"key":"108_CR81","first-page":"1400","volume":"23","author":"P. Baumer","year":"1999","unstructured":"Baumer P, Brocard JF, Kohn W, et al.: Severe chronic interstitial nephritis associated with Crohn\u2019s disease, but not with mesalazine? Gastroenterol Clin Biol 1999, 23:1400\u20131402.","journal-title":"Gastroenterol Clin Biol"},{"key":"108_CR82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2169\/internalmedicine.47.0287","volume":"47","author":"A. Unal","year":"2008","unstructured":"Unal A, Sipahioglu MH, Akgun H, et al.: Crohn\u2019s disease complicated by granulomatous interstitial nephritis, choroidal neovascularization, and central retinal vein occlusion. Intern Med 2008, 47:103\u2013107.","journal-title":"Intern Med"},{"key":"108_CR83","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1468-1331.2007.01718.x","volume":"14","author":"R. Scheid","year":"2007","unstructured":"Scheid R, Teich N: Neurologic manifestations of ulcerative colitis. Eur J Neurol 2007, 14:483\u2013493.","journal-title":"Eur J Neurol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-008-0108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-008-0108-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-008-0108-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T10:59:33Z","timestamp":1709463573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-008-0108-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,25]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1007\/s11894-008-0108-6","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,25]]}}}